Growth equity does not show up when things are loud or sloppy. It shows up when the signal is clean, the data behaves, and the operators know exactly what business they are in. ClinTrial Research earned that signal. On Dec 17, 2025, the Research Triangle Park-based clinical site network closed a growth equity round led by Tarsadia Investments, and the timing says more than any press quote ever could.
ClinTrial Research was built in 2024 with a blunt thesis. Clinical trials do not fail because the science collapses. They fail because execution bleeds out. Physicians churn, patients disappear, protocols expand, staffing thins, and sites drown in admin work. ClinTrial Research stepped into that friction as a next gen Site Management Organization, embedding directly inside physician practices so doctors can stay focused on care while the business of trials runs clean and controlled in the background.
Samuel Searcy leads as CEO with the instincts of someone who has built, sold, legislated, and scaled inside this industry. Jennifer Yevoli serves as Chief Legal Officer, bringing deep healthcare and regulatory muscle forged across law and operations. Subhash Gumber, MD, PhD, FACG anchors the model as President and CMO with decades of real clinical credibility. Wendy Tomlinson operates as COO with 25+ years of trial execution experience. This is not a theory stack. This is lived experience stacked correctly.
The network proves the point. Behavioral health and CNS, respiratory, internal medicine, gastroenterology, nephrology, ophthalmology. Board certified physicians including Sonal Arora, Sharad Vora, Haresh Tharwani, Vinod Jindal, and Amit Kumar are not accessories here. They are the product. ClinTrial Research wraps staffing, compliance, analytics, and infrastructure around real practices in real communities, solving the 90% problem where most physicians never run a 2nd trial.
Technology is where the math changes. The partnership with Trilly AI unlocked HIPAA-compliant matching across major EHR systems, driving higher enrollment, fewer screen failures, less manual chart review, stronger site revenue, and improved diversity. Enrollment rates up. Screen failures down 73%. Efficiency up 90%. This is where AI stops being marketing and starts being operational leverage.
Tarsadia Investments noticed. Rishi Reddy and his team spent years dissecting the site network landscape, and growth equity only moves when conviction meets proof. This marks ClinTrial Research’s 1st institutional round, landing inside a market tracking from $8.77B in 2024 toward $15.77B by 2034 at a 7.85% CAGR. Clinical trials run on trust, data, and execution. ClinTrial Research is quietly building infrastructure where most still see chaos.
Startups, startup funding, venture capital, research, data, data driven, healthcare, health tech, compliance, infrastructure, technology, innovation, tech ecosystem, startup ecosystem, hiring, tech hiring, DCTalks.
